Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2009

View Archived Issues

Durasphere bulking agent effective for recurrent pyelonephritis in kidney transplant patients

Duquesne University discloses novel tricyclic compounds for cancer treatment

New heterocyclic compounds in early development at AstraZeneca for the treatment of cancer

Shanghai Hengrui describes new protein kinase inhibitors in early development

GSK researchers describe new histamine H3 receptor antagonists for cognitive impairment

Merck & Co. claims new guanylate cyclase activators for the treatment of hypertension

Siga presents novel antiviral drugs active against hemorrhagic fever viruses

Exenatide induces weight loss and glucose normalization in nondiabetic obese patients

Alseres receives SPA agreement from FDA for phase III Altropane trial

Intercell initiates phase I Streptococcus pneumoniae vaccine trial

Seattle Genetics enters antibody-drug conjugate collaboration with Millennium

Positive phase II findings for Reolysin with radiation in advanced cancers

Watson launches Rapaflo

Novel JAK1/JAK2 inhibitor developed by Cytopia for the treatment of myeloproliferative disorders

Danisco BioActives and Sigma-Tau collaborate on necrotizing enterocolitis drug

Serentis starts phase II first-in-class SRD-441 study for eczema

FDA accepts Theravance's telavancin NDA for hospital-acquired pneumonia

Genta completes patient enrollment in global phase III Genasense trial

Health Canada approves once-daily Prezista as part of combination HIV therapy

TRITON-TIMI 38 data on prasugrel in acute coronary syndromes further analyzed

Aplenzin extended-release tablets available in the U.S.

Cardiovascular risk with PPAR agonist aleglitazar assessed in diabetes patients

FDA Advisory Committee provides opinion on Serdolect in schizophrenia

Daiichi Sankyo and Eli Lilly launch Efient in the U.K.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...